SOFI vs STRO · P/E 39, rev $619.4M vs rev $62.0M
SoFi Technologies Inc. (SOFI) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
SoFi Technologies Inc. (SOFI) is a credit services company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported SOFI revenue for 2025-12-31 was $619.4M. Net income was $481.3M. Revenue was up 23.1% from 2024-12-31 to 2025-12-31. SOFI currently screens at market cap $22.25B and trailing P/E 38.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
SOFI currently screens at market cap $22.25B and trailing P/E 38.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the SOFI and STRO stock pages for the full models.
Not investment advice.